Report

In Vitro Fertilization Market Analysis

The in vitro fertilization market size is valued at USD 28.64 billion in 2025 and is forecast to reach USD 42.47 billion by 2030, advancing at an 8.21% CAGR. Expanding infertility prevalence, delayed parenthood in developed nations and steady improvements in assisted-reproductive technologies propel this climb. North America leads revenue generation, helped by widening insurance mandates and employer-sponsored fertility benefits, while Asia-Pacific delivers the quickest expansion on the back of medical-tourism inflows and supportive policy changes. Industry participants deepen investments in laboratory automation, non-invasive genetic testing and AI-enabled embryo assessment, which together shorten cycle times and improve success rates. However, high treatment costs, uneven third-party payer coverage and evolving ethical standards surrounding embryo status remain persistent headwinds to adoption.

Global In Vitro Fertilization Market Trends and Insights



Increasing Infertility Prevalence

Secondary infertility now surpasses primary infertility across much of Asia-Pacific, largely due to rising polycystic ovary syndrome incidence and lifestyle factors. China alone counts up to 11.8 million infertile couples and adds as many as 1.9 million new cases each year Nature. Similar trends in the Philippines and urban India are prompting rapid capacity additions, with more than 60 fertility centers opening annually across India. Because infertility is treated as essential rather than discretionary care, demand demonstrates resilience to economic cycles and underpins steady procedure volumes globally.

Rising Average Maternal Age

Women increasingly pursue parenthood in their late-30s and 40s, ages where natural fecundity drops sharply. Studies from the University of Copenhagen show that a higher count of primitive endoderm stem cells in early embryos correlates with greater implantation success, critical for older patients. Declining genetic-testing costs enable pre-implantation screening to spread from fewer than 6% to roughly 25% of all cycles, while oocyte-rejuvenation techniques under development in Singapore aim to restore aged-egg competence. Corporate fertility benefits mirror this societal change, with nearly one-third of US employers now offering IVF coverages.

High Treatment Cost and Patchy Insurance Coverage

Typical US cycle prices range from USD 12,000 to USD 30,000, and total outlays can top USD 60,000 when multiple attempts are needed, pushing many patients to seek treatment in lower-cost hubs such as Singapore or India. California's upcoming mandate is expected to raise insurer costs by hundreds of millions of dollars annually, potentially inflating premiums. In China, actuarial studies estimate that adding ART to the public insurance catalogue would consume up to 6% of current fund balances, illustrating the fiscal hurdles to universal coverage. Payment-on-success models, including USD 15,000 "live-birth or no-pay" packages marketed by automation start-ups, aim to ease affordability but remain in early stages of adoption.

Other drivers and restraints analyzed in the detailed report include:

Technological Advances in Assisted Reproductive Technologies / Growing Acceptance of Non-Traditional Family Structures / Ethical and Religious Concerns Over Embryo Manipulation /

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Instruments contributed USD 16 billion of 2024 revenue, equal to 55.67% in vitro fertilization market share. Continued capital spending on incubators, micromanipulators and imaging systems sustains this lead even as replacement cycles lengthen. The consumables category, however, is projected to post a brisk 10.45% CAGR, the fastest within the entire in vitro fertilization market. Adoption of sterile, single-use culture ware mitigates contamination risk and dovetails with fully enclosed work-stations that minimize manual handling. Advanced incubators integrate AI algorithms to auto-correct temperature and pH fluctuations every 10 minutes, raising blastocyst yield rates in early commercial deployments. Specialized reagents incorporating glycan-coated micro-beads mimic oviduct conditions and boost sperm viability; yet their incremental cost keeps the overall reagent segment in mature-growth territory. Complementary imaging modules such as EmbryoScope+ now capture nearly 7,200 minutes of time-lapse data per cycle, feeding machine-learning models that rank embryo competence.

The consumables boom reinforces recurring revenue models for suppliers who historically depended on one-off equipment sales. Investments in automated cryo-systems and vitrification media improve post-thaw survival to above 95%, supporting elective single-embryo transfer guidelines aimed at lowering multiple-birth complications. Greater standardization also appeals to networks operating in multiple jurisdictions, where harmonized protocols speed accreditation and insurer contracting. As a result, the in vitro fertilization market size linked to consumables is poised to outstrip instrument spending growth over the forecast period.

Fresh non-donor cycles represented 32.14% of completed procedures in 2024, retaining primacy due to immediate transfer and lower storage costs. Enhanced ovarian-stimulation protocols and real-time embryo-grading software keep their success rates competitive, ensuring they remain the backbone of the in vitro fertilization market. Donor egg cycles, though, will expand at 10.33% CAGR as delayed motherhood elevates demand for higher-quality oocytes. Countries with permissive donor legislation and strong clinical infrastructures, such as Spain and the United States, attract growing medical-tourism flows for these services. Frozen-thawed cycles gain ground thanks to refined vitrification and the clinical shift toward single-embryo transfer, which lowers twin-birth risk and neonatal complications.

Donor-sperm cycles are likewise rising in tandem with increasing acceptance of single motherhood and same-sex parenting. Regulatory scrutiny has tightened after isolated incidents of specimen mislabeling, prompting wider deployment of RFID-based chain-of-identity systems. Ethical sourcing and enhanced donor-screening standards reduce reputational risk for clinics and gamete banks, supporting long-term growth in this portion of the in vitro fertilization industry.

The in Vitro Fertilization Market Report is Segmented by Product (Reagents, Instruments, and Consumables & Disposables), Cycle Type (Fresh IVF Cycles - Non-Donor, and More), Procedure Type (Conventional IVF, and More), End User (Fertility Clinics, and More), Geography (North America, Europe, Asia-Pacific, The Middle East and Africa, and South America). The Market Forecasts are Provided in Terms of Value (USD).

Geography Analysis

North America captured 42.45% of 2024 revenue, reflecting mature insurance markets, robust corporate fertility benefits and a leadership position in AI-driven laboratory technology. California's comprehensive SB 729 mandate, effective July 2025, exemplifies the region's regulatory support: it obliges large group health plans to cover up to three egg retrievals and unlimited transfers. Innovation clusters in the United States host first-in-human trials of autonomous micromanipulation and non-invasive genome screening tools, helping clinics command premium pricing. Nonetheless, divergent state-level rulings on embryo status inject operational uncertainty and may spur patient outflows to more permissive jurisdictions.

Asia-Pacific registers the fastest expansion at a projected 9.54% CAGR through 2030, with regional in vitro fertilization market size expected to top USD 13.5 billion by 2028. China confronts an estimated 11.8 million infertile couples and is evaluating integration of ART into social insurance, a move that would entail initial outlays equal to as much as 6% of current fund balances. India, buoyed by the Assisted Reproduction Technology Act and strong private-equity appetite, is on track to lift service revenue nearly fourfold between 2020 and 2030. Medical tourism flourishes, as Singapore's average cycle price of USD 10,200 stands at nearly quadruple the USD 2,700 prevailing in major Indian metros, prompting cross-border patient flows into lower-cost destinations.

Europe delivers steady growth anchored by universal healthcare frameworks and favorable reimbursement in select nations. Norway, for instance, subsidizes up to three cycles per woman, while countries such as Spain leverage liberal donor-egg regulations and modern clinic infrastructure to attract international clientele. Eastern European providers offer mid-price alternatives in the EUR 1,600-5,800 range that appeal to Western Europeans seeking shorter waiting lists. Harmonized safety protocols set by the European Society of Human Reproduction and Embryology bolster patient confidence and sustain medical-tourism inflows despite varied national age and embryo-limit rules.

List of Companies Covered in this Report:

Cook Group / The Cooper Companies / Fujifilm Holdings Corp. / Genea Biomedx / Hamilton Thorne / Merck / Nikon Corp. / Thermo Fisher Scientific / Vitrolife / Oxford Gene Technology (Sysmex) / Rocket Medical / Boston IVF / Virtus Health Ltd / IVI RMA Global / Ovascience / Agilent Technologies / Illumina / Natera / INVO Bioscience / Ferring Pharmaceuticals /

Additional Benefits:

The market estimate (ME) sheet in Excel format /
3 months of analyst support /